Top

Lung

Published in:

01-06-2016

Polymorphisms of the Stem Cell Marker Gene CD133 and the Risk of Lung Cancer in Chinese Population

Authors: Qing-Feng Liu, Zhi-Fei Zhang, Guang-Jie Hou, Guang-Yu Yang, Yi He

Published in: Lung | Issue 3/2016

Abstract

Objective

To explore the association of functional single-nucleotide polymorphisms (SNPs) of CD133 with the risk of lung cancer.

Methods

We conducted a hospital-based, case–control study of 1017 lung cancer patients and 1035 cancer-free controls frequency-matched by age and sex. Four functional CD133 SNPs (rs2240688 A > C, rs10022537 T > A, rs7686732 C > G, and rs3130 C > T) were selected and genotyped. Unconditional univariate and multivariate logistic regression analyses were carried out to evaluate the associations of genotypes of CD133 SNPs with lung cancer risk.

Results

Compared with rs2240688 AA genotype, the variant AC/CC genotypes were associated with a statistically increased risk of lung cancer under a recessive model (adjusted odds ratio 1.19; 95 % confidence interval 1.01–1.42). The risk remained in patients with other histology types, but not with adenocarcinoma and squamous cell cancers.

Conclusions

These findings suggest that SNP rs2240688 A > C of CD133 may be a potential biomarker for genetic susceptibility to lung cancer, but require further research with larger populations.

Jemal A, Center MM, DeSantis C et al (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev 19(8):1893–1907. doi:10.1158/1055-9965.EPI-10-0437 CrossRef

Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. doi:10.3322/caac.21262 CrossRefPubMed

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29. doi:10.3322/caac.20138 CrossRefPubMed

Spitz MR, Hong WK, Amos CI et al (2007) A risk model for prediction of lung cancer. J Natl Cancer Inst 99(9):715–726. doi:10.1093/jnci/djk153 CrossRefPubMed

Thun M, Peto R, Boreham J et al (2012) Stages of the cigarette epidemic on entering its second century. Tob Control 21(2):96–101. doi:10.1136/tobaccocontrol-2011-050294 CrossRefPubMed

Kim CF, Dirks PB (2008) Cancer and stem cell biology: how tightly intertwined? Cell Stem Cell 3(2):147–150. doi:10.1016/j.stem.2008.07.012 CrossRefPubMed

Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8(10):755–768. doi:10.1038/nrc2499 CrossRefPubMed

Dick JE (2008) Stem cell concepts renew cancer research. Blood 112(13):4793–4807. doi:10.1182/blood-2008-08-077941 CrossRefPubMed

Yin AH, Miraglia S, Zanjani ED et al (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90(12):5002–5012PubMed

10.

Ferrandina G, Martinelli E, Petrillo M et al (2009) CD133 antigen expression in ovarian cancer. BMC Cancer 9:221. doi:10.1186/1471-2407-9-221 CrossRefPubMedPubMedCentral

11.

Abols A, Ducena K, Zayakin P et al (2014) Survey of autoantibody responses against tumor-associated antigens in thyroid cancer. Cancer Biomark 14(5):361–369. doi:10.3233/CBM-140413 PubMed

12.

Bertolini G, Roz L, Perego P et al (2009) Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106(38):16281–16286. doi:10.1073/pnas.0905653106 CrossRefPubMedPubMedCentral

13.

Li Z (2013) CD133: a stem cell biomarker and beyond. Exp Hematol Oncol 2(1):17. doi:10.1186/2162-3619-2-17 CrossRefPubMedPubMedCentral

14.

Hu N, Wang C, Ng D et al (2009) Genomic characterization of esophageal squamous cell carcinoma from a high-risk population in China. Cancer Res 69(14):5908–5917. doi:10.1158/0008-5472.CAN-08-4622 CrossRefPubMedPubMedCentral

15.

Chung CC, Chanock SJ (2011) Current status of genome-wide association studies in cancer. Hum Genet 130(1):59–78. doi:10.1007/s00439-011-1030-9 CrossRefPubMed

16.

Pohl A, El-Khoueiry A, Yang D et al (2013) Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenomics J 13(2):173–180. doi:10.1038/tpj.2011.61 CrossRefPubMedPubMedCentral

17.

Woo T, Okudela K, Mitsui H et al (2010) Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol 4(1):32–42PubMedPubMedCentral

18.

Cheng M, Yang L, Yang R et al (2013) A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression. Carcinogenesis 34(10):2292–2299. doi:10.1093/carcin/bgt181 CrossRefPubMed

19.

Wang Q, Liu H, Xiong H et al (2015) Polymorphisms at the microRNA binding-site of the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer. Mol Carcinog 54(6):449–458. doi:10.1002/mc.22113 CrossRefPubMed

20.

Okudela K, Woo T, Mitsui H et al (2012) Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and beta-catenin, in primary lung adenocarcinoma—their prognostic significance. Pathol Int 62(12):792–801. doi:10.1111/pin.12019 CrossRefPubMed

21.

Corbeil D, Roper K, Fargeas CA et al (2001) Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2(2):82–91CrossRefPubMed

22.

Yu X, Lin Y, Yan X et al (2011) CD133, stem cells, and cancer stem cells: myth or reality? Curr Colorectal Cancer Rep 7(4):253–259. doi:10.1007/s11888-011-0106-1 CrossRefPubMedPubMedCentral

23.

Hu Z, Wu C, Shi Y et al (2011) A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet 43(8):792–796. doi:10.1038/ng.875 CrossRefPubMed

Title: Polymorphisms of the Stem Cell Marker Gene CD133 and the Risk of Lung Cancer in Chinese Population
Authors: Qing-Feng Liu
Zhi-Fei Zhang
Guang-Jie Hou
Guang-Yu Yang
Yi He
Publication date: 01-06-2016
Publisher: Springer US
Published in: Lung / Issue 3/2016
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-016-9876-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Polymorphisms of the Stem Cell Marker Gene CD133 and the Risk of Lung Cancer in Chinese Population

Abstract

Objective

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2016

Airway Epithelial Cell Release of GABA is Regulated by Protein Kinase A

Cells and Culture Systems Used to Model the Small Airway Epithelium

Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure

Chronic Thromboembolic Pulmonary Hypertension: A Worldwide View of How Far We Have Come

Down-Regulation of Soluble α-Klotho is Associated with Reduction in Serum Irisin Levels in Chronic Obstructive Pulmonary Disease

Complications and Yield of Computed Tomography-Guided Transthoracic Core Needle Biopsy of Lung Nodules at a High-Volume Academic Center in an Endemic Coccidioidomycosis Area

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page